Effects of exercise snacks on cardiorespiratory fitness, body composition, and blood lipids in adults across different age groups: a systematic review and meta-analysis.

J Nutr Health AgingAug 10, 2026 (epub)
Clinical ResearchCardiologyGeriatricsPreventive Medicine / Public HealthOpen access

Lidian Meng, Yichen Li, Jiayi Chen et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the impact of exercise snacks on cardiorespiratory fitness, body composition, and blood lipids in adults across various age groups. The analysis included 21 studies with 921 participants. Results indicated significant improvements in maximal oxygen uptake (VO2 max; g = 1.04) and peak power output (PPO; g = 0.68), while body fat percentage increased overall.

Key findings

  • Exercise snacks significantly improved VO2 max (g = 1.04, 95% CI = 0.68-1.39).
  • Peak power output also improved significantly (g = 0.68, 95% CI = 0.25-1.10).
  • Body fat percentage showed an overall increase (g = 0.51, 95% CI = 0.01-1.02).
  • No significant effects were observed for total cholesterol or triglycerides.

Why it matters

Understanding the effects of exercise snacks on fitness and body composition can inform strategies for improving health outcomes in adults, particularly in promoting cardiorespiratory fitness across different age groups.

Source

PubMed · PMID 42571752Free full text on PubMed Central

Published in J Nutr Health Aging. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.